MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MDWD
CUSIPN/A
Phone972-8932-4010
Debt
Debt-to-Equity RatioN/A
Current Ratio6.07
Quick Ratio5.75
Price-To-Earnings
Trailing P/E Ratio-10.08
Forward P/E Ratio-8.22
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.50 million
Price / Sales67.63
Cash FlowN/A
Price / CashN/A
Book Value$0.36 per share
Price / Book17.36
Profitability
EPS (Most Recent Fiscal Year)($0.62)
Net Income$-22,140,000.00
Net Margins-904.12%
Return on Equity-226.62%
Return on Assets-36.64%
Miscellaneous
Employees76
Outstanding Shares27,050,000
Market Cap$170.40
Mediwound (NASDAQ:MDWD) Frequently Asked Questions
What is Mediwound's stock symbol?
Mediwound trades on the NASDAQ under the ticker symbol "MDWD."
How were Mediwound's earnings last quarter?
Mediwound Ltd (NASDAQ:MDWD) issued its quarterly earnings results on Thursday, May, 10th. The biopharmaceutical company reported ($0.17) EPS for the quarter, hitting analysts' consensus estimates of ($0.17). The biopharmaceutical company had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.57 million. Mediwound had a negative net margin of 904.12% and a negative return on equity of 226.62%. View Mediwound's Earnings History.
When is Mediwound's next earnings date?
What price target have analysts set for MDWD?
5 analysts have issued 1 year price objectives for Mediwound's shares. Their predictions range from $8.00 to $14.00. On average, they expect Mediwound's share price to reach $10.00 in the next year. This suggests a possible upside of 60.0% from the stock's current price. View Analyst Ratings for Mediwound.
What is the consensus analysts' recommendation for Mediwound?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Mediwound's key competitors?
Some companies that are related to Mediwound include Chromadex (CDXC), Foamix Pharmaceuticals (FOMX), Natural Alternatives International (NAII), Pharmacyte Biotech (PMCB), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), ImmuDyne (IMMD), FitLife Brands (FTLF), Nutra Pharma (NPHC), Tauriga Sciences (TAUG), True Drinks Holdings, Inc Common Stock (TRUU), Entia Biosciences (ERGO) and Rock Creek Pharmaceuticals (RCPIQ).
Who are Mediwound's key executives?
Mediwound's management team includes the folowing people:
- Mr. Gal Cohen, Pres & CEO (Age 45)
- Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 72)
- Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 46)
- Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 52)
- Dr. Ety Klinger, Chief R&D Officer (Age 56)
Has Mediwound been receiving favorable news coverage?
Media headlines about MDWD stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mediwound earned a media sentiment score of 0.16 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 46.25 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Mediwound?
Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mediwound's stock price today?
One share of MDWD stock can currently be purchased for approximately $6.25.
How big of a company is Mediwound?
Mediwound has a market capitalization of $170.40 million and generates $2.50 million in revenue each year. The biopharmaceutical company earns $-22,140,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Mediwound employs 76 workers across the globe.
How can I contact Mediwound?
Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]
MarketBeat Community Rating for Mediwound (NASDAQ MDWD)
MarketBeat's community ratings are surveys of what our community members think about Mediwound and other stocks. Vote "Outperform" if you believe MDWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
